Is ESLA or EXEL more undervalued in 2026?

CirclFi compares Estrella Immunopharma, Inc. (ESLA) and Exelixis, Inc. (EXEL) using 13 institutional-grade valuation models. ESLA has a Quality of Company score of 3.1/10 while EXEL scores 10.0/10.

Which is a better buy — ESLA or EXEL?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do ESLA and EXEL valuations compare?

ESLA at $1.14 and EXEL at $51.45 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

ESLA vs EXEL Valuation Comparison 2026 — Intrinsic Value Analysis

ESLA

Biotechnology

Estrella Immunopharma, Inc.

Quality

3.1

out of 10

Value Trap

SAFE

Price

$1.14

Last close

Models

8/13

Active

EXEL

Biotechnology

Exelixis, Inc.

Quality

10.0

out of 10

Value Trap

SAFE

Price

$51.45

Last close

Models

12/13

Active

Model-by-Model Comparison

Model	Type	ESLA Fair Value	ESLA Upside	EXEL Fair Value	EXEL Upside
Bayesian DCF	Intrinsic	$0.32	-71.7%	$43.90	-14.7%
Earnings Power Value	Intrinsic	—	—	$29.37	-42.9%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$1.51	+35.0%	$78.68	+52.9%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for ESLA vs EXEL — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

ESLA vs EXEL — Which Stock Is More Undervalued?

EXEL scores higher with a 10.0/10 quality rating vs ESLA's 3.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Estrella Immunopharma, Inc. (ESLA) and Exelixis, Inc. (EXEL) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

ESLA currently trades at $1.14 with a QOC of 3.1/10, while EXEL trades at $51.45 with a QOC of 10.0/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).